Eli Lilly forecast annual profit largely above Wall Street estimates on Thursday, banking on the launch of its popular ...

Workday said on Wednesday it will cut around 1,750 jobs, or 8.5% of its current workforce, as the human capital management ...

Real-time index price for S&P 500 Value (IVX), along with buy or sell indicators, analysis, charts, historical performance, ...

Vijay Pande, PhD, founding investor of Andreessen Horowitz's Bio + Health fund and a general partner with the tech venture capital firm , discusses how AI’s uptake in healthcare will shape its ...

Let's look at five pharma and drug companies ... at where Eli Lilly and Company (NYSE:LLY) stands against the other dividend stocks. During a time of great excitement about AI-driven capital ...

Eli Lilly and Company (NYSE: LLY) announced today that the U.S. Food and Drug Administration (FDA ... progressed on a prior aromatase inhibitor (AI), with or without a CDK4/6 inhibitor.

Since the first, seminal randomised controlled trial (RCT) in inflammatory bowel disease (IBD) in 1955,1 the central tenets for high-quality clinical trials have been recognised as robust and ...

Sanofi is tapping San Francisco-based Atomwise for a new AI-fuelled drug discovery deal ... including Merck & Co, Eli Lilly, and AbbVie. In 2019 they struck a major deal with China's Hansoh ...

Follow along for live updates on stocks, bonds and markets, including the Dow Jones Industrial Average, S&P 500 and Nasdaq Composite.

As we observe World Cancer Day today, let us look at some of the trends in cancer therapeutics expected to improve cancer ...

A recent Morgan Stanley Research report suggested that even modest improvements in early-stage drug development success rates with AI and machine ... with pharma groups Eli Lilly and Merck ...

H.C. Wainwright reiterated a Buy rating on Silence Therapeutics (NASDAQ:SLN) stock with a price target of $75.00, representing significant upside from the current price of $5.33. According to ...